Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Expert Consensus Statements on the Management of Breast Cancer During Pregnancy (PrBC)

ESMO Expert Consensus Statements on the Management of breast cancer during pregnancy (PrBC)

Published 10 August 2023 - Ann Oncol
Authors: S. Loibl, H.A. Azim Jr., T Bachelot, P. Berveiller, A. Bosch, E. Cardonick, C. Denkert, M.J. Halaska, M. Hoeltzenbein, A.L.V. Johansson, C. Maggen, U.R. Markert, F. Peccatori, P. Poortmans, E. Saloustros, C. Saura, P. Schmid, E. Stamatakis, M. van den Heuvel-Eibrink, M. van Gerwen, V. Vandecaveye, G. Pentheroudakis, G. Curigliano, F. Amant

The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on this challenging topic.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.